Literature DB >> 1259924

Significance of haematological parameters in the non-Hodgkin's malignant lymphomas.

C D Bloomfield, R W McKenna, R D Brunning.   

Abstract

Blood findings at diagnosis, in 140 adults with lymphoma, were correlated with bone marrow involvement and survival. An abnormal haemoglobin, leucocyte count or platelet count was found in 57% of patients. Lymphocytopenia occurred in 46%. All patients with thrombocytopenia or neutropenia, 69% with leucopenia and 63% with anaemia had marrow involvement with lymphoma. Marrow involvement in histiocytic and stem cell lymphoma was always associated with anaemia. Marrow involvement in poorly differentiated lymphocytic lymphoma (PDL) was associated with anaemia, thrombocytopenia, leucopenia, lymphocytopenia or lymphoma cells in the blood in 93% of patients. Bone marrow involvement was found in only 13% of patients with normal haematological parameters. In the absence of marrow involvement blood abnormalities at diagnosis did not generally correlate with survival. However, among patients with diffuse PDL who had marrow involvement, anaemia, thrombocytopenia and leucopenia adversely affected survival. Lymphocytopenia did not correlate with survival.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1259924     DOI: 10.1111/j.1365-2141.1976.tb01873.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  7 in total

1.  [Significance of clinical and laboratory chemical parameters for the course and prognosis of non-Hodgkin's lymphomas].

Authors:  B Steinke; J Mau
Journal:  Klin Wochenschr       Date:  1986-05-15

2.  Enhancement of the International prognostic index with β2-microglobulin, platelet count and red blood cell distribution width: a new prognostic model for diffuse large B-cell lymphoma in the rituximab era.

Authors:  Haizhu Chen; Qiaofeng Zhong; Yu Zhou; Yan Qin; Jianliang Yang; Peng Liu; Xiaohui He; Shengyu Zhou; Changgong Zhang; Lin Gui; Sheng Yang; Liqiang Zhou; Yuankai Shi
Journal:  BMC Cancer       Date:  2022-05-27       Impact factor: 4.638

3.  Characteristics of patients with systemic lupus erythematosus (SLE) and non-Hodgkin's lymphoma (NHL).

Authors:  Jennifer K King; Karen H Costenbader
Journal:  Clin Rheumatol       Date:  2007-02-13       Impact factor: 3.650

4.  Anemia as a useful biomarker in patients with diffuse large B-cell lymphoma treated with R-CHOP immunochemotherapy.

Authors:  Junshik Hong; Hyun Seon Woo; Hyunchul Kim; Hee Kyung Ahn; Sun Jin Sym; Jinny Park; Jeong Yeal Ahn; Eun Kyung Cho; Dong Bok Shin; Jae Hoon Lee
Journal:  Cancer Sci       Date:  2014-11-05       Impact factor: 6.716

5.  Clinical features and prognostic factors of primary bone marrow lymphoma.

Authors:  Gangjian Wang; Yu Chang; Xiaolong Wu; Xin Li; Ling Li; Lei Zhang; Xiaorui Fu; Zhenchang Sun; Xudong Zhang; Mingzh Zhang
Journal:  Cancer Manag Res       Date:  2019-03-29       Impact factor: 3.989

6.  Prognostic factors in non-Hodgkin's lymphoma: the importance of symptomatic stage as an adjunct to the Kiel histopathological classification.

Authors:  R C Leonard; J Cuzick; I C MacLennan; R I Vanhegan; P H Mackie; C V McCormick
Journal:  Br J Cancer       Date:  1983-01       Impact factor: 7.640

7.  Red blood cell distribution width and platelet counts are independent prognostic factors and improve the predictive ability of IPI score in diffuse large B-cell lymphoma patients.

Authors:  Manman Li; Hailong Xia; Huimin Zheng; Yafeng Li; Jun Liu; Linhui Hu; Jingrong Li; Yangyang Ding; Lianfang Pu; Qianle Gui; Yijie Zheng; Zhimin Zhai; Shudao Xiong
Journal:  BMC Cancer       Date:  2019-11-11       Impact factor: 4.430

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.